After decades of being starved of innovative treatments for serious conditions like cancer, diabetes and kidney disease, China’s 1.4 billion people are becoming a prime target for Eli Lilly and other pharmaceutical companies.
The university said it has hired 33 research faculty to help under the “Grand Challenges” program in precision health, an initiative it rolled out two years ago.
The Indianapolis-based pharmaceutical giant said it plans to acquire ARMO BioSciences Inc., which is working on treatments that activate the immune system of cancer patients to recognize and eradicate tumors.
The ads for the metastatic breast cancer drug Verzenio show women in their 50s and 60s looking resolute and indomitable, surrounded by smiling friends and family.
The Indianapolis-based health system will present details Tuesday to the Carmel Plan Commission for the two-story, 88,000-square-foot building.
Lawmakers stripped a provision from the bill that would have boosted the cigarette tax from 99 cents a pack to $2.99.
The program is for patients with Stage 3 or Stage 4 cancer who had not had success with traditional treatments. Under the program, scientists analyze patients’ genome, leading to a personalized treatment plan.
Scientists are reporting progress on a blood test to detect many types of cancer at an early stage, including some of the most deadly ones that lack screening tools.
The company said the funds would help it test its lead compound in late-stage clinical trials, allowing surgeons to detect cancerous cells with the help of fluorescent dyes.
After struggling for more than 20 years to develop cancer drugs without success, West Lafayette-based Endocyte Inc. is pausing it own R&D efforts to concentrate on a potential blockbuster drug from a German chemical company.
U.S. regulators have approved a new medicine for treating a common type of breast cancer after it has spread to other parts of the body.
Researchers at Indiana University and Purdue University have received $2.55 million from Susan G. Komen to study possible new treatments.
li Lilly and Co.’s experimental breast cancer drug abemaciclib, when combined with standard therapy, slowed the progression of tumors in patients with an advanced form of the disease.
Community Health Network’s new Cancer Center North, which will have its grand opening Saturday is designed to lift patients’ spirits as much as kill cancer cells.
Lifestyle and heredity get the most blame for cancer, but new research suggests random chance plays a bigger role than people realize.
Hutchison China MediTech Ltd., the biotechnology company that has a partnership with Eli Lilly and Co., on Friday reported positive late-stage results for its drug to treat colorectal cancer.
Purdue University Professor You-Yeon Won’s development, called radio-luminescent nanoparticles, is designed to enhance the cancer-cell-killing effects of radiation treatment.
Teva Pharmaceuticals Industries Ltd.’s proposed generic version infringes a patent on the multi-billion-dollar patent, the U.S. Court of Appeals for the Federal Circuit ruled.
The point of chemo is to cure me. But these are not gentle chemicals. They sweep through my body like a tornado, with side effects that range from annoying to horrendous. But I have no choice.
Lartruvo is the first front-line therapy approved by the FDA to treat soft tissue sarcomas since doxorubicin more than 40 years ago.
